Maintenance of response with guselkumab for up to 3 years' treatment in the phase 3 VOYAGE 1 trial of patients with plaque psoriasis

被引：0
|
作者：
Griffiths, C. E. [1 ]
Papp, K. A. [2 ]
Song, M. [3 ]
Randazzo, B. [3 ]
Li, S. [3 ]
Shen, Y. -K. [3 ]
Han, C. [3 ]
Blauvelt, A. [4 ]
机构：
[1] Univ Manchester, Dermatol Ctr, Manchester, Lancs, England
[2] K Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] Oregon Med Res Ctr, Portland, OR USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷
关键词：
Guselkumab; Psoriasis; VOYAGE;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P108
引用
收藏
页码：49 / 50
页数：2
相关论文
共 50 条
  • [21] Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Kimball, Alexa B.
    Randazzo, Bruce
    Song, Michael
    Li, Shu
    Shen, Yaung-Kaung
    Blauvelt, Andrew
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 826 - 832
  • [22] Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 VOYAGE 1 study
    Blauvelt, Andrew
    Papp, Kim
    Griffiths, Christopher E. M.
    Randazzo, Bruce
    Wasfi, Yasmine
    Shen, Yaung-Kaung
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [23] Improvement in absolute psoriasis area and severity index score through 3 years of continuous treatment with guselkumab in VOYAGE 1
    Puig, L.
    Gordon, K. B.
    Tsai, T. -F.
    Thaci, D.
    Gooderham, M.
    Fakharzadeh, S.
    Li, S.
    Shen, Y. -K.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 108 - 108
  • [24] Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies
    Gordon, K. B.
    Blauvelt, A.
    Foley, P.
    Song, M.
    Wasfi, Y.
    Randazzo, B.
    Shen, Y. K.
    You, Y.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (01) : 132 - 139
  • [25] Maintenance of treatment response in chronic plaque psoriasis patients continuing treatment or discontinuing treatment with tildrakizumab in a 64-week, randomized controlled, phase 3 trial
    Papp, K.
    Kimball, A. B.
    Tyring, S.
    Sinclair, R.
    Metha, Anish
    Cichanowitz, N.
    Li, Q.
    Green, S.
    La Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB164 - AB164
  • [26] Maintenance of complete skin clearance throughout 3 years of continuous guselkumab treatment in patients with moderate-to-severe psoriasis: A post hoc analysis of 5-year data from the VOYAGE 1 trial
    Costanzo, Antonio
    Conrad, Curdin
    Gramiccia, Talia
    Jazra, Maria
    de Jong, Elke M. G. J.
    Iversen, Lars
    Ozturk, Bulent
    Wapenaar, Robert
    Wegner, Sven
    Torres, Tiago
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB108 - AB108
  • [27] Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3-VOYAGE 1 study
    Blauvelt, A.
    Papp, K.
    Griffiths, C. E. M.
    Randazzo, B.
    Wasfi, Y.
    Shen, Y.
    Li, S.
    Kimball, A. B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 40 - 40
  • [28] Maintenance of response after guselkumab withdrawal in patients with moderate-to-severe psoriasis: A post hoc analysis of the VOYAGE 2 trial
    Conrad, Curdin
    Koerber, Andreas
    Schaekel, Knut
    Thaci, Diamant
    Joks, Gero
    Jazra, Maria
    Wegner, Sven
    Wapenaar, Robert
    Paul, Carle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB107 - AB107
  • [29] Improvement in absolute psoriasis area and severity index through 5 years of continuous treatment with guselkumab in the VOYAGE 1 trial
    Puig, Luis
    Strober, Bruce
    Tsai, Tsen-Fang
    Thaci, Diamant
    Gooderham, Melinda
    Miller, Megan
    Yang, Ya-Wen
    You, Yin
    Shen, Yaung-Kaung
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB154 - AB154
  • [30] Low-risk of serious infections and infections of interest in psoriasis patients treated with Guselkumab for 5 years in VOYAGE 1 and 2 phase 3 trials
    Langley, R.
    Thaci, D.
    Blauvelt, A.
    Tsai, T. -F.
    Miller, M.
    Yu, J.
    Shen, Y. -K.
    You, Y.
    Yang, Y. -W.
    Papp, K. A.
    Puig, L.
    Foley, P.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 35 - 35
12345